US6416738B1
(en)
|
1973-12-07 |
2002-07-09 |
Neorx Corporation |
Pretargeting methods and compounds
|
US6075010A
(en)
*
|
1992-06-09 |
2000-06-13 |
Neorx Corporation |
Small molecular weight ligand-hexose containing clearing agents
|
US5576195A
(en)
*
|
1985-11-01 |
1996-11-19 |
Xoma Corporation |
Vectors with pectate lyase signal sequence
|
US5618920A
(en)
*
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US5869620A
(en)
*
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US6025165A
(en)
*
|
1991-11-25 |
2000-02-15 |
Enzon, Inc. |
Methods for producing multivalent antigen-binding proteins
|
DE69334255D1
(de)
*
|
1992-02-06 |
2009-02-12 |
Novartis Vaccines & Diagnostic |
Marker für Krebs und biosynthetisches Bindeprotein dafür
|
US5911969A
(en)
|
1992-06-09 |
1999-06-15 |
Neorx Corporation |
Pretargeting protocols for enhanced localization of active agents to target sites
|
US6217869B1
(en)
|
1992-06-09 |
2001-04-17 |
Neorx Corporation |
Pretargeting methods and compounds
|
US6358490B2
(en)
|
1992-06-09 |
2002-03-19 |
Neorx Corporation |
Three-step pretargeting methods and compounds
|
US6329507B1
(en)
*
|
1992-08-21 |
2001-12-11 |
The Dow Chemical Company |
Dimer and multimer forms of single chain polypeptides
|
WO1994012520A1
(en)
*
|
1992-11-20 |
1994-06-09 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
US6015897A
(en)
*
|
1993-12-07 |
2000-01-18 |
Neorx Corporation |
Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
|
JPH09506106A
(ja)
*
|
1993-12-07 |
1997-06-17 |
ネオルクス コーポレーション |
プレターゲティング方法及び化合物
|
US20050214309A1
(en)
*
|
1994-03-18 |
2005-09-29 |
Hinrichs Steven H |
Methods and compositions for modulating transcription factor activity
|
SE9401460D0
(sv)
*
|
1994-04-28 |
1994-04-28 |
Ferring Ab |
Antigen/antibody specificity exhanger
|
US6040137A
(en)
|
1995-04-27 |
2000-03-21 |
Tripep Ab |
Antigen/antibody specification exchanger
|
US6660842B1
(en)
|
1994-04-28 |
2003-12-09 |
Tripep Ab |
Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
|
US6933366B2
(en)
|
1996-12-27 |
2005-08-23 |
Tripep Ab |
Specificity exchangers that redirect antibodies to bacterial adhesion receptors
|
WO1996013583A2
(en)
*
|
1994-10-20 |
1996-05-09 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Targeted hetero-association of recombinant proteins to multi-functional complexes
|
US6172045B1
(en)
|
1994-12-07 |
2001-01-09 |
Neorx Corporation |
Cluster clearing agents
|
US6908903B1
(en)
|
1994-12-07 |
2005-06-21 |
Aletheon Pharmaceuticals, Inc. |
Cluster clearing agents
|
US7399837B2
(en)
|
1995-12-22 |
2008-07-15 |
Smithkline Beecham Corporation |
Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
|
US5693323A
(en)
*
|
1994-12-23 |
1997-12-02 |
Smithkline Beecham Corporation |
Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
|
WO1996037621A2
(en)
*
|
1995-05-23 |
1996-11-28 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Multimeric proteins
|
GB9718358D0
(en)
*
|
1997-08-30 |
1997-11-05 |
Univ Leeds |
Chemical modification
|
US7105307B2
(en)
|
1997-08-30 |
2006-09-12 |
Cyclacel, Ltd. |
Compositions and methods for screening for modulators of enzymatic activity
|
CA2313028A1
(en)
*
|
1997-12-01 |
1999-06-10 |
Cfy Biomedicals, Inc. |
Multivalent recombinant antibodies for treating hrv infections
|
US6204537B1
(en)
|
1998-10-01 |
2001-03-20 |
Micron Technology, Inc. |
ESD protection scheme
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
US20030035798A1
(en)
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
US6432673B1
(en)
*
|
1998-12-07 |
2002-08-13 |
Zymogenetics, Inc. |
Growth factor homolog ZVEGF3
|
US7550143B2
(en)
*
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US20030143234A1
(en)
*
|
1999-08-20 |
2003-07-31 |
Wenyuan Shi |
Anti-microbial targeting chimeric pharmaceutical
|
US7569542B2
(en)
|
1999-08-20 |
2009-08-04 |
The Regents Of The University Of California |
Anti-microbial targeting chimeric pharmaceutical
|
WO2002102854A2
(en)
|
2001-06-20 |
2002-12-27 |
Morphosys Ag |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
US7022323B2
(en)
|
2001-06-26 |
2006-04-04 |
Progenics Pharmaceuticals, Inc. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
DE10133071A1
(de)
*
|
2001-07-07 |
2003-03-06 |
Alexander Cherkasky |
Antigene, Rezeptoren, Liganden oder ihre Regionen kombiniert mit proteolytischer Aktivität
|
EP1578917A4
(en)
|
2001-07-19 |
2008-01-23 |
Perlan Therapeutics Inc |
MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
WO2003018749A2
(en)
|
2001-08-22 |
2003-03-06 |
Shengfeng Li |
Compositions and methods for generating antigen-binding units
|
US7175983B2
(en)
*
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
EP2075256A2
(en)
|
2002-01-14 |
2009-07-01 |
William Herman |
Multispecific binding molecules
|
US7335359B2
(en)
|
2003-02-06 |
2008-02-26 |
Tripep Ab |
Glycosylated specificity exchangers
|
JP2007516157A
(ja)
|
2003-02-06 |
2007-06-21 |
トリペップ アクチ ボラゲット |
グリコシル化された抗原/抗体又はリガンド/受容体特異性交換体
|
TWI353991B
(en)
*
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
CA2522690A1
(en)
*
|
2003-05-06 |
2004-11-25 |
Syntonix Pharmaceuticals, Inc. |
Inhibition of drug binding to serum albumin
|
US7348004B2
(en)
*
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
DK2298347T3
(en)
|
2003-05-06 |
2016-01-11 |
Biogen Hemophilia Inc |
COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
US8551480B2
(en)
*
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
US7875598B2
(en)
*
|
2004-03-04 |
2011-01-25 |
The Regents Of The University Of California |
Compositions useful for the treatment of microbial infections
|
JP4991544B2
(ja)
|
2004-08-23 |
2012-08-01 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
ストレス応答を媒介するためのペプチド阻害剤
|
EP1824513A4
(en)
*
|
2004-11-04 |
2010-06-09 |
Fibron Ltd |
TREATMENT OF B-CELL TUMORS
|
US20120276100A1
(en)
*
|
2005-04-06 |
2012-11-01 |
Ibc Pharmaceuticals, Inc. |
Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity
|
EP1885396A2
(en)
*
|
2005-05-04 |
2008-02-13 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against cd55 and cd59 and uses thereof
|
US7989219B2
(en)
|
2005-05-31 |
2011-08-02 |
Canon Kabushiki Kaisha |
Bispecific capturing molecule
|
KR100832773B1
(ko)
|
2005-11-18 |
2008-05-27 |
주식회사 아이지세라피 |
기능성 Fv 항체 절편 제조 방법
|
AU2007227218A1
(en)
|
2006-03-22 |
2007-09-27 |
Viral Logic Systems Technology Corp. |
Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
|
WO2007112005A2
(en)
*
|
2006-03-24 |
2007-10-04 |
Syntonix Pharmaceuticals, Inc. |
Pc5 as a factor ix propeptide processing enzyme
|
US20080131431A1
(en)
*
|
2006-05-15 |
2008-06-05 |
Viral Logic Systems Technology Corp. |
CD47 related compositions and methods for treating immunological diseases and disorders
|
US8377448B2
(en)
*
|
2006-05-15 |
2013-02-19 |
The Board Of Trustees Of The Leland Standford Junior University |
CD47 related compositions and methods for treating immunological diseases and disorders
|
EP2046384A4
(en)
|
2006-06-15 |
2009-12-02 |
Fibron Ltd |
ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
|
US10118970B2
(en)
|
2006-08-30 |
2018-11-06 |
Genentech, Inc. |
Multispecific antibodies
|
EP2061488B1
(en)
|
2006-09-06 |
2014-07-30 |
The Regents of the University of California |
Selectively targeted antimicrobial peptides and the use thereof
|
EP2072527A1
(en)
*
|
2007-12-21 |
2009-06-24 |
Altonabiotec AG |
Fusion polypeptides comprising a SHBG dimerization component and uses thereof
|
BRPI0910854A2
(pt)
|
2008-03-28 |
2015-10-06 |
Glaxosmithkline Llc |
métodos de tratamento
|
JP5796831B2
(ja)
|
2008-09-03 |
2015-10-21 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体
|
AR079944A1
(es)
*
|
2010-01-20 |
2012-02-29 |
Boehringer Ingelheim Int |
Anticuerpo neutralizante de la actividad de un anticoagulante
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
AP2013007046A0
(en)
|
2011-03-30 |
2013-08-31 |
Boehringer Ingelheim Int |
Anticoagulant antidotes
|
US20140088017A1
(en)
|
2011-05-23 |
2014-03-27 |
Yeda Research And Development Co., Ltd. |
Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
US10036747B2
(en)
*
|
2011-11-22 |
2018-07-31 |
University Of Maryland, Baltimore |
Lambodies with high affinity and selectivity for glycans and uses therefor
|
CA2861003C
(en)
*
|
2012-01-13 |
2023-03-28 |
Julius-Maximilians-Universitat Wurzburg |
Dual antigen-induced bipartite functional complementation
|
EP3492095A1
(en)
|
2012-04-01 |
2019-06-05 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
AU2014228938B2
(en)
|
2013-03-15 |
2019-05-02 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
DK3027204T3
(da)
|
2013-07-29 |
2022-04-19 |
2Seventy Bio Inc |
Flerdelte signaleringsproteiner og anvendelser deraf
|
US9243294B2
(en)
|
2013-09-30 |
2016-01-26 |
Hadasit Medical Research Services And Development Ltd. |
Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
|
CN105744955B
(zh)
|
2013-11-25 |
2020-03-20 |
希凯姆生物治疗有限公司 |
用于癌症治疗的包含抗ceacam1抗体和抗pd抗体的组合物
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
CA2939121C
(en)
|
2014-01-28 |
2020-11-24 |
Mayo Foundation For Medical Education And Research |
Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
US20170174764A1
(en)
|
2014-03-27 |
2017-06-22 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
MX366359B
(es)
|
2014-04-27 |
2019-07-05 |
Ccam Biotherapeutics Ltd |
Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
JP2016002009A
(ja)
*
|
2014-06-13 |
2016-01-12 |
国立大学法人名古屋大学 |
タグ付抗体
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
JP7084138B2
(ja)
|
2014-08-19 |
2022-06-14 |
ノバルティス アーゲー |
癌処置に使用するための抗cd123キメラ抗原受容体(car)
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CU20170052A7
(es)
|
2014-10-14 |
2017-11-07 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
WO2016157195A1
(en)
|
2015-04-01 |
2016-10-06 |
Hadasit Medical Research Services And Development Ltd. |
Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for treatment of liver disorders
|
RU2021121771A
(ru)
|
2015-04-08 |
2022-01-12 |
Новартис Аг |
Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
SI3317301T1
(sl)
|
2015-07-29 |
2021-10-29 |
Novartis Ag |
Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
|
JP6861418B2
(ja)
|
2015-09-02 |
2021-04-28 |
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド |
ヒトt細胞免疫グロブリン及びitimドメイン(tigit)に特異的な抗体
|
EP3362093A4
(en)
|
2015-10-13 |
2019-05-08 |
Technion Research & Development Foundation Limited |
MONOCLONAL ANTIBODIES NEUTRALIZING HEPARANASE
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
WO2017106810A2
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
US20210198368A1
(en)
|
2016-01-21 |
2021-07-01 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
BR112018067522A2
(pt)
|
2016-03-01 |
2019-02-05 |
Univ Of Rijeka Faculty Of Medicine |
anticorpos específicos para receptor de poliovírus humano (pvr)
|
BR112018067679A2
(pt)
|
2016-03-04 |
2019-01-15 |
Novartis Ag |
células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
HRP20230457T1
(hr)
|
2016-04-15 |
2023-07-21 |
Novartis Ag |
Pripravci i postupci za selektivnu ekspresiju kimernih antigenskih receptora
|
GB201609235D0
(en)
|
2016-05-25 |
2016-07-06 |
Univ Cape Town |
Production of a horseradish peroxidase-IGG fusion protein
|
EP3464375A2
(en)
|
2016-06-02 |
2019-04-10 |
Novartis AG |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
AU2017295886C1
(en)
|
2016-07-15 |
2024-01-25 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
US20190151365A1
(en)
|
2016-07-28 |
2019-05-23 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and pd-1 inhibitors
|
US20190161542A1
(en)
|
2016-08-01 |
2019-05-30 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
WO2018226339A1
(en)
|
2017-06-06 |
2018-12-13 |
Glaxosmithkline Llc |
Biopharmaceutical compositions and methods for pediatric patients
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
WO2018237157A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
CN111163798A
(zh)
|
2017-07-20 |
2020-05-15 |
诺华股份有限公司 |
用于抗lag-3抗体的给药方案及其用途
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
EP3723787A4
(en)
|
2017-12-14 |
2021-09-01 |
Bluebird Bio, Inc. |
DARIC INTERLEUKIN RECEPTORS
|
NZ765453A
(en)
*
|
2017-12-22 |
2024-03-22 |
Hanmi Pharmaceutical Co Ltd |
Therapeutic enzyme fusion protein having novel structure and use thereof
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
JP2021522801A
(ja)
|
2018-05-09 |
2021-09-02 |
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド |
ヒトネクチン4に特異的な抗体
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
EP3797120A1
(en)
|
2018-05-21 |
2021-03-31 |
Compass Therapeutics LLC |
Compositions and methods for enhancing the killing of target cells by nk cells
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CA3098420A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Binding molecules against bcma and uses thereof
|
EP3806962A1
(en)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma chimeric antigen receptors and uses thereof
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
JP2022514315A
(ja)
|
2018-12-20 |
2022-02-10 |
ノバルティス アーゲー |
3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体を含む投与計画及び薬剤組み合わせ
|
AU2019400978A1
(en)
|
2018-12-20 |
2021-06-24 |
Novartis Ag |
Extended low dose regimens for MDM2 inhibitors
|
WO2020144697A1
(en)
|
2019-01-13 |
2020-07-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to human nectin-2
|
CA3124935A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
KR20210129672A
(ko)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
EP3927371A1
(en)
|
2019-02-22 |
2021-12-29 |
Novartis AG |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
MX2021011830A
(es)
|
2019-03-29 |
2022-01-24 |
Atarga Llc |
Anticuerpo anti fgf23.
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
CA3140142A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Trispecific binding molecules against bcma and uses thereof
|
US20210040197A1
(en)
|
2019-08-08 |
2021-02-11 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
KR20220103947A
(ko)
|
2019-10-21 |
2022-07-25 |
노파르티스 아게 |
베네토클락스 및 tim-3 억제제를 사용한 조합 요법
|
JP2022553830A
(ja)
|
2019-11-05 |
2022-12-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
N末端scFv多重特異性結合分子
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
MX2022007754A
(es)
|
2019-12-20 |
2022-07-19 |
Regeneron Pharma |
Nuevos agonistas de il2 y metodos de uso de estos.
|
CN115052662A
(zh)
|
2019-12-20 |
2022-09-13 |
诺华股份有限公司 |
抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
|
MX2022008763A
(es)
|
2020-01-17 |
2022-07-27 |
Novartis Ag |
Combinacion que comprende un inhibidor de tim-3 y un agente hipometilante para usarse en el tratamiento del sindrome mielodisplasico o leucemia mielomonocitica cronica.
|
EP4090762A1
(en)
|
2020-01-17 |
2022-11-23 |
Becton, Dickinson and Company |
Methods and compositions for single cell secretomics
|
WO2021173995A2
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
CN116249549A
(zh)
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
CA3179348A1
(en)
|
2020-04-06 |
2021-10-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
|
US20230242647A1
(en)
|
2020-05-01 |
2023-08-03 |
Novartis Ag |
Engineered immunoglobulins
|
EP4149963A1
(en)
|
2020-05-12 |
2023-03-22 |
Regeneron Pharmaceuticals, Inc. |
Novel il10 agonists and methods of use thereof
|
JP2023531676A
(ja)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン
|
MX2023000547A
(es)
|
2020-07-16 |
2023-02-13 |
Novartis Ag |
Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
CN116134027A
(zh)
|
2020-08-03 |
2023-05-16 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022097065A2
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
KR20230104651A
(ko)
|
2020-11-06 |
2023-07-10 |
노파르티스 아게 |
Cd19 결합 분자 및 이의 용도
|
EP4240494A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
CA3206413A1
(en)
|
2021-02-11 |
2022-08-18 |
Pinchas TSUKERMAN |
Antibodies against cd112r and uses thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
US20220372168A1
(en)
|
2021-05-04 |
2022-11-24 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
WO2022269451A1
(en)
|
2021-06-22 |
2022-12-29 |
Novartis Ag |
Bispecific antibodies for use in treatment of hidradenitis suppurativa
|
TW202321282A
(zh)
|
2021-07-19 |
2023-06-01 |
美商再生元醫藥公司 |
Il12受體促效劑及其使用方法
|
AU2022331241A1
(en)
|
2021-08-16 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Novel il27 receptor agonists and methods of use thereof
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023073599A1
(en)
|
2021-10-28 |
2023-05-04 |
Novartis Ag |
Engineered fc variants
|
TW202334223A
(zh)
|
2021-11-11 |
2023-09-01 |
美商再生元醫藥公司 |
Cd20-pd1結合分子及其使用方法
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
WO2023148707A1
(en)
|
2022-02-07 |
2023-08-10 |
Yeda Research And Development Co. Ltd. |
Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023220647A1
(en)
|
2022-05-11 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023230594A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
WO2023235848A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024040247A1
(en)
|
2022-08-18 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Interferon proproteins and uses thereof
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|